Drug Approval | February 03, 2022
USFDA approves first generic of Restasis
Restasis has been approved for use in the U.S. for nearly 20 years, but until today, there was no approved generic product of this drug
Restasis has been approved for use in the U.S. for nearly 20 years, but until today, there was no approved generic product of this drug
A National Tele Mental Health Programme is being launched to address mental health issues. We spoke to healthcare industry leaders who shared their outlook
The immunogens being tested in IAVI G002 were developed by scientific teams at IAVI and Scripps Research and will be delivered via Moderna's mRNA technology
The covid health center will be managed and administered by the district administration of Ballari
The six-layer packaging ensures that external media such as bacteria, light and air do not contaminate the liquid
APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types
Previously, the use of the drug was limited to patients requiring hospitalization
An article by a team of 12 Italian and 9 Russian scientists led by Francesco Vaia, Director of the Spallanzani Institute and Alexander Gintsburg, Director of the Gamaleya Center, has been published in medRxiv
Quviviq is a dual orexin receptor antagonist, which blocks the binding of the wake-promoting neuropeptides orexins and is thought to turn down overactive wakefulness, as opposed to treatments that generally sedate the brain
The global multi-center phase-II clinical trial will be a 36-week, multi-center, randomized, double-blind, placebo-controlled trial, followed by a 36-week open-label extension period
Subscribe To Our Newsletter & Stay Updated
